Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091 September 19, 2023
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL) September 19, 2023
Nurix Announces Strategic Collaboration with Seagen Combining Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance a New Class of Cancer Therapeutics September 19, 2023
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics September 19, 2023
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology September 19, 2023
Patient Dosing with MT-302 initiated in Ph 1 Study for Advanced or Metastatic Epithelial Tumors September 19, 2023
Ph 2 EVOKE-02 Study Of Trodelvy + KEYTRUDA Demonstrates Promising Clinical Activity In 1L mNSCLC September 19, 2023
Datopotamab deruxtecan + Imfinzi showed promising clinical activity in 1L advanced NSCLC in TROPION-Lung04 Ph 1b trial September 19, 2023
Enhertu demonstrated strong and durable tumor responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Ph 2 trial September 19, 2023
New Lumakras® (Sotorasib) Plus Chemotherapy Data In First-Line KRAS G12C NSCLC announced September 19, 2023
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated mNSCLC in HERTHENA-Lung01 Ph 2 Trial September 19, 2023
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML September 19, 2023
Enhertu recommended for approval in the EU by CHMP for patients with HER2-mutant advanced NSCLC September 19, 2023
Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with NSCLC at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemo September 19, 2023
